Transgene SA (EPA:TNG)
0.7400
-0.0260 (-3.39%)
Apr 2, 2026, 5:35 PM CET
Transgene Revenue
In the year 2025, Transgene had annual revenue of 7.21M EUR with 13.49% growth. Transgene had revenue of 2.63M in the half year ending December 31, 2025, a decrease of -16.13%.
Revenue
7.21M
Revenue Growth
+13.49%
P/S Ratio
28.10
Revenue / Employee
49.05K
Employees
147
Market Cap
202.63M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.21M | 857.00K | 13.49% |
| Dec 31, 2024 | 6.35M | -1.55M | -19.58% |
| Dec 31, 2023 | 7.90M | -2.44M | -23.63% |
| Dec 31, 2022 | 10.34M | -6.90M | -40.00% |
| Dec 31, 2021 | 17.24M | 7.67M | 80.08% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Valneva SE | 174.66M |
| Cellectis | 67.79M |
| Genfit | 45.13M |
| MedinCell | 32.44M |
| Adocia | 12.88M |
| Innate Pharma | 9.01M |
| Sensorion | 5.81M |
| ABIONYX Pharma | 4.10M |
Transgene News
- 10 days ago - Transgene SA (STU:TGNA) Full Year 2025 Earnings Call Highlights: Strategic Financial Moves and ... - GuruFocus
- 10 days ago - Full Year 2025 Transgene SA Earnings Call Transcript - GuruFocus
- 7 months ago - Transgene SA (FRA:TGNA) (Half Year 2025) Earnings Call Highlights: Strategic Focus on TG4050 ... - GuruFocus
- 7 months ago - Half Year 2025 Transgene SA Earnings Call Transcript - GuruFocus
- 1 year ago - Half Year 2024 Transgene SA Earnings Call Transcript - GuruFocus
- 3 years ago - Transgene Announces New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio - Business Wire
- 3 years ago - Transgene Receives Approval to Start a Phase I Trial of TG6050, a Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration - Business Wire
- 3 years ago - Transgene and BioInvent Joint Paper on BT-001 Wins JITC “Best Oncolytic and Local Immunotherapy Paper” Award for 2022 - Business Wire